Search

Search Results for "Therapeutics"

AAO 2021 Late Breakers: DAVIO and NORSE-2

The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes Sense

Diabetic Eye Disease: What's Next for Your Patients?

Continuous Dosing in LADDER

International Perspectives: DME

Diabetic Eye Disease: What's Next for Your Patients?

Rishi Singh, MD; and Nathan Steinle, MD

Thumbnail for wflor

Spark Therapeutics

Paulo Falabella, MD, PhD

Thumbnail for deefiv

Topical Steroids and Ocular Inflammation

Thumbnail for rineed

Onset and Progression of Atrophic Age-Related Macular Degeneration: Toxic byproducts of Vision

Thumbnail for genop

EyeGate II Delivery System

Thumbnail for eporu

ReSure Sealant for Cataract Patient with Previous RK

Arun C. Gulani MD, Arup Chakrabarti, MD

Thumbnail for legom

In-Service Video for Mitosol

Mobius Therapeutics

The Promise of Dry AMD Therapies thumbnail

The Promise of Dry AMD Therapies

Joan W. Miller, MD

Novel Approaches to Wet AMD Management thumbnail

Novel Approaches to Wet AMD Management

Ramin Tadayoni MD, PhD

Inflammasome Inhibitor Moving Through the Pipeline thumbnail

Inflammasome Inhibitor Moving Through the Pipeline

Liangbo Linus Shen, MD

The Future of Treating Diabetic Eye Disease? thumbnail

The Future of Treating Diabetic Eye Disease?

Joseph Allen, OD, FAAO, Dipl ABO

Pivotal Data For the Treatement of XLRP thumbnail

Pivotal Data For the Treatement of XLRP

Robert A. Sisk MD

Thumbnail for fopap

Topical Ophthalmic Drug Delivery Device

Amorphex Therapeutics LLC

Phase 2 STORM Trial Shows Positive Outcomes thumbnail

Phase 2 STORM Trial Shows Positive Outcomes

Francis Price, MD

Optogenetics for RP: 126-Week Data thumbnail

Optogenetics for RP: 126-Week Data

David S. Liao, MD, PhD

Optogenetics for RP: 12 Month Data thumbnail

Optogenetics for RP: 12-Month Data

Allen Ho, MD

View More